胃康灵胶囊联合雷贝拉唑治疗胃溃疡的临床效果

Clinical Effect of Weikangling Capsule Combined with Rabeprazole on Gastric Ulcer

目的 探究对胃溃疡的患者采用雷贝拉唑联合胃康灵胶囊治疗的临床效果。方法 回顾性选取2020年10月—2022年8月临洮县人民医院收治的125例胃溃疡患者的临床资料。根据治疗方法的不同将患者分为两组,研究组(n=63)采用雷贝拉唑联合胃康灵胶囊治疗,对照组(n=62)采用雷贝拉唑治疗。对比两组治疗效果、不良反应、炎症因子指标以及视觉模拟评分法(Visual Analogue Scale,VAS)评分。结果 研究组治疗总有效率(95.24%)高于对照组(83.87%),差异有统计学意义(χ^(2)=4.333,P<0.05)。两组不良反应总发生率对比(9.52%vs 12.90%),差异无统计学意义(χ^(2)=0.359,P>0.05)。治疗后两组白细胞介素-6、肿瘤坏死因子-α、白细胞介素-8及VAS评分较治疗前均降低,且研究组均低于对照组,差异有统计学意义(P均<0.05)。结论 应用雷贝拉唑联合胃康灵胶囊治疗胃溃疡具有明显的效果。

Objective To explore the effect of rabeprazole combined with Weikangling capsule on patients with gastric ulcer.Methods The clinical data of one hundred and twenty-five patients with gastric ulcer admitted from October 2020 to August 2022 in Lintao County People's Hospital were retrospectively selected,and the patients were divided into two groups according to different treatment method.The study group(n=63) was treated with rabeprazole combined with Weikangling capsule,and the control group(n=62) was treated with rabeprazole.Treatment effect,adverse reactions,inflammatory factors,and Visual Analogue Scale(VAS) score of two groups were compared.Results The total effective rate of the study group(95.24%) was higher than that of the control group(83.87%),and the difference was statistically significant(χ^(2)=4.333,P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(9.52% vs 12.90%)(χ^(2)=0.359,P>0.05).After treatment,the levels of interleukin-6,tumor necrosis factor-α,interleukin-8 and VAS scores in two groups were lower than those before treatment,and the study group were lower than those in the control group,and the differences were statistically significant(all P<0.05).Conclusion The combined application of rabeprazole and Weikangling capsule has obvious effect in the treatmentof gastric ulcer.